Skip to content

A Randomized Prospective Controlled Clinical Study for effect of Jiuwei Qingzhi Gao in the Treatment of Non-alcoholic Fatty Liver Disease

A Randomized Prospective Controlled Clinical Study for effect of Jiuwei Qingzhi Gao in the Treatment of Non-alcoholic Fatty Liver Disease

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900021508
Enrollment
Unknown
Registered
2019-02-24
Start date
2019-02-24
Completion date
Unknown
Last updated
2019-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic Fatty Liver Disease

Interventions

Jiuwei Qingzhi Gao:Jiuwei Qingzhi Gao orally
Yishanfu:Yishanfu orally
Guidance with Dietary and exercise :Education and guidance with Dietary and exercise

Sponsors

Jiangsu Provincial Hospital of Chinese Medicine (Affiliated Hospital of Nanjing University of Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. The patients met the diagnostic criteria of nonalcoholic fatty liver disease in the Guidelines for Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (2018 edition); 2. ALT > 42U/L, GGT > 50U/L; 3. Triglyceride > 1.71 umol/l, LDL > 3.1 umol/l or diagnosed as metabolic syndrome; 4. Fatty liver is indicated by ultrasound or MRI, or by liver biopsy; 5. Aged between 18 years and 50 years. 6. Patients who agree to participate in this clinical trial and voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe alcoholism (average daily intake of alcohol for women and women (> 20 g) and male (> 30 g); 2. Complicated with tumors, hypothyroidism, nephropathy, heart disease; 3. Complicated infection with viral hepatitis C or B, decompensated cirrhosis; 4. Active hepatitis caused by autoimmune hepatitis, hereditary liver disease and other causes; 5. NAFLD induced by drugs used in the past year, includes amiodarone, sodium valproate, tamoxifen, methotrexate, corticosteroids or antiretroviral agents; 6. ALT>500U/L or AST>500U/L; 7. Glycated hemoglobin > 8%. 8. Pregnancy.

Design outcomes

Primary

MeasureTime frame
Biochemical indexes of serum;B ultrasound of Liver ;Liver elastography;

Countries

China

Contacts

Public ContactQiao fei

Jiangsu Provincial Hospital of Chinese Medicine (Affiliated Hospital of Nanjing University of Chinese Medicine)

qf88888@aliyun.com+86 025 86617141

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026